ERBB2 and breast carcinoma: Activating mutations of PIK3CA have been detected in ~40% of HR+/HER2- breast cancers, and more than 50% of breast cancer patients harbour oncogenic alterations of at least one member of the PIK3CA pathway [10, 11].